MEF2C and colon carcinoma: Emerging evidence has implicated MAML1 as an exciting key transcriptional coactivators in other signal transduction pathways, including muscle differentiation and myopathies (MEF2C), tumor suppressor pathway (p53), and colon carcinoma survival (β-catenin).